Drilldown: Medicines

Baclofen (1) · Famotidine (1) · Hydrochlorothiazide (1)

Lioresal (oral, intrathecal pump), Ozobax / Fleqsuvy (oral suspension), Gablofen (intrathecal), Lyvispah (oral granules) (1) · Microzide; mostly prescribed generically (1) · Pepcid, Pepcid AC, Pepcid Complete (1)

[[:Category:Antihypertensives|Antihypertensive]] (1) · [[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) · [[:Category:Antispastics|Antispastic]] (1) · [[:Category:GABA-B receptor agonists|GABA-B receptor agonist]] (1) · [[:Category:H2_receptor_antagonists|Histamine H2 receptor antagonist]] (1) · [[:Category:Skeletal muscle relaxants|Skeletal muscle relaxant (centrally-acting)]] (1) · [[:Category:Thiazide_diuretics|Thiazide diuretic]] (1)

None (1) · '"`UNIQ--vote-00000138-QINU`"' Decreases urinary calcium (used in stone prevention); raises serum uric acid, glucose, and lipids modestly; non-anion-gap hypokalemic metabolic alkalosis is the characteristic electrolyte pattern'"`UNIQ--ref-00000139-QINU`"'. (1) · '"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1)

'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1) · '"`UNIQ--vote-0000013A-QINU`"', '"`UNIQ--vote-0000013B-QINU`"', '"`UNIQ--vote-0000013C-QINU`"', '"`UNIQ--vote-0000013D-QINU`"' (1) · '"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"' (1)

12.5-25 mg PO once daily (1) · 20 mg PO twice daily, or 40 mg at bedtime (1) · Oral: 5 mg PO TID, titrate by 5 mg per dose every 3 days. Intrathecal: bolus test dose, then continuous infusion via implanted pump (1)

10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) · 12.5 mg capsules; 12.5, 25, 50 mg tablets (1) · Tablets 5, 10, 20 mg; oral suspension 5 mg/5 mL (Ozobax, Fleqsuvy); intrathecal injection 50, 500, 1000, 2000 mcg/mL (Lioresal Intrathecal, Gablofen); oral granules (Lyvispah) (1)

160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications (1) · 50 mg/d (hypertension); up to 200 mg/d (edema) (1) · 80 mg/day oral (higher off-label) (1)

intrathecal (via implanted infusion pump) (1) · IV (1) · Oral (3)

1 hour PO; minutes IV (1) · 1-2 hours (oral) (1) · Diuresis at 2 hours; antihypertensive effect within days, max at 3-4 weeks (1)

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) · 3-4 hours'"`UNIQ--ref-00000026-QINU`"' (1) · 6-15 hours'"`UNIQ--ref-0000013E-QINU`"' (1)

40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"' (1) · 65-75% (oral)'"`UNIQ--ref-0000013F-QINU`"' (1) · ~70-85% (oral)'"`UNIQ--ref-00000027-QINU`"' (1)

None (1) · Generally considered safe; widely used. Cleared in lactation at low levels.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

OTC (10-20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) · [[USLegal:Prescription only|Rx-only]] in US (1) · [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance'"`UNIQ--ref-00000028-QINU`"' (1)